Project Grant HT94252410515
Award Date
9/30/24
Completion Date
9/29/27
Dollars Obligated
$559K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02111, USA
Similar Awards
The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
The Defense Health Agency awarded a $828,591 Project Grant under CFDA 12.420, the Military Medical Research and Development program, to Duke University. The grant supports research titled "Targeting the Tumor Microenvironment to Enhance Immunotherapy for SCLC", with a performance period from May 1, 2025 to April 30, 2027. This research aims to transform healthcare for military service members, veterans, and the public by advancing innovative biomedical investigations focused on...
This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,158,989.00 to Yale University to conduct research on optimizing adoptive cellular immunotherapy for rare melanomas. The research project commenced on September 1, 2023 and is scheduled for completion by August 31, 2026. The key objectives of this grant-funded research are to advance innovative medical solutions for rare forms of melanoma that are difficult to...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...
This Project Grant award of $172,355 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of Connecticut Health Center to investigate spatial transcriptomic and proteomic shifts in tumor-infiltrating immunocytes, with the goal of enhancing melanoma therapeutics. The research aims to chart a path for improved treatment of melanoma by mapping changes in gene expression and protein levels within immune cells...
The Defense Health Agency awarded a $724,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Duke University. The grant, titled "Targeting Dormancy-Associated Immune Tolerance to Eliminate Residual Breast Cancer," will fund advanced biomedical research to transform healthcare for military service members, veterans, and the broader public. The research, to be conducted at Duke University's Office of Research Administration Division from March...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The federal Project Grant award of $3,120,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by Thomas Jefferson University's Sidney Kimmel Medical College on novel tumor-targeted immunotherapies against metastatic uveal melanoma. This 4-year award, running from September 1, 2025 to August 31, 2029, aims to transform healthcare for military service members, veterans, and the broader public through innovative...